Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback